268 related articles for article (PubMed ID: 20799989)
21. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: A case report and literature review.
Li J; Zhou J; Liu Y; Sun X; Song W
J Cancer Res Ther; 2020 Sep; 16(5):1020-1026. PubMed ID: 33004743
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
25. The clinical approach toward giant cell tumor of bone.
van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone: A 1 to 12-Year Follow-up Study.
Greenberg DD; Lee FY
Am J Clin Oncol; 2019 Mar; 42(3):231-237. PubMed ID: 30811352
[TBL] [Abstract][Full Text] [Related]
27. Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.
Balla P; Moskovszky L; Sapi Z; Forsyth R; Knowles H; Athanasou NA; Szendroi M; Kopper L; Rajnai H; Pinter F; Petak I; Benassi MS; Picci P; Conti A; Krenacs T
Histopathology; 2011 Sep; 59(3):376-89. PubMed ID: 22034878
[TBL] [Abstract][Full Text] [Related]
29. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
30. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
[TBL] [Abstract][Full Text] [Related]
31. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
[TBL] [Abstract][Full Text] [Related]
32. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
[TBL] [Abstract][Full Text] [Related]
33. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
34. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
36. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yamada T; Muguruma H; Yano S; Ikuta K; Ogino H; Kakiuchi S; Hanibuchi M; Uehara H; Nishioka Y; Sone S
Mol Cancer Ther; 2009 Jan; 8(1):119-26. PubMed ID: 19139120
[TBL] [Abstract][Full Text] [Related]
37. Local administration of zoledronic acid for giant cell tumor of bone.
Nishisho T; Hanaoka N; Miyagi R; Sakai T; Toki S; Takahashi M; Kenji E; Yasui N; Sairyo K
Orthopedics; 2015 Jan; 38(1):e25-30. PubMed ID: 25611416
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
39. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
40. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
